阿尔茨海默病相关认知障碍药物靶点研究进展

doi:10.3969/j.issn.1003-9198.2026.02.003

Abstract

Abstract: Recent studies have found that cognitive impairment caused by Alzheimer’s disease (AD) may result from multiple mechanisms acting in concert. This article summaries the pathogenesis of cognitive impairment related to AD, including the β-amyloid hypothesis, Tau protein hypothesis, neuroinflammation hypothesis, synaptic injury, neuronal dysfunction, and neuroplasticity changes, as well as the APOE gene. And further explores the possible origins of the disease and related drug therapeutic targets. Finally, this paper proposes that future efforts need to comprehensively integrate the different pathogenic mechanisms of AD, and a multi-target therapeutic model may be a new direction for the prevention and treatment of AD-related cognitive impairment.

Key words: cognitive impairment, Alzheimer’s disease, neurodegenerative diseases, therapeutic target

CLC Number:

R 749.16

SUN Yang, GUO Ying. Research progress on drug targets for Alzheimer’s disease-related cognitive impairment[J]. Practical Geriatrics, 2026, 40(2): 116-120.

References

[1] MAGANA-RAMIREZ C M, GILLEN D L, HOM C L, et al. Neuropsychiatric symptoms and emerging dementia in people with down syndrome and older adults[J]. Alzheimers Dement, 2025, 21(11):e70871.
[2] TAKEDA T, UMEHARA H, MATSUMOTO Y, et al. Schizophrenia and cognitive dysfunction[J]. J Med Invest, 2024, 71(3/4): 205-209.
[3] LEE N, YOUN K, KWON H, et al. Fucoxanthin suppresses amyloid-β and pyroglutamate-3-Aβ accumulation by modulating the PI3K/AKT/GSK-3β signaling pathway[J]. Food Funct, 2025, 16(23): 9102-9117.
[4] CHOE K, ALI J, PARK H Y, et al. The mGluR2/3 agonist xanthurenic acid improves memory, attention, and synaptic deficits by modulating glutamate release in Alzheimer’s disease model[J]. Acta Pharmacol Sin, 2025. DOI: 10.1038/s41401-025-01671-y.
[5] JIANG S, HIJAZI S, SÁRKÁNY B, et al. Pathological tau alters head direction signaling and induces spatial disorientation[J]. Cell Rep, 2025, 44(12): 116610.
[6] CHOI D J, MURALI S, KWON W, et al. Astrocytic Sox9 overexpression in Alzheimer’s disease mouse models promotes Aβ plaque phagocytosis and preserves cognitive function[J]. Nat Neurosci, 2025. DOI: 10.1038/s41593-025-02115-w.
[7] ZHOU Y, SONG W M, ANDHEY P S, et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease[J]. Nat Med, 2020, 26(1):131-142.
[8] YU C, WANG W, SHI L, et al. 27-Hydroxycholesterol triggers microglial senescence subsequent to iron over-loading contributes to brain aging, suppressed by Deferoxamine[J]. NPJ Aging, 2025. DOI: 10.1038/s41514-025-00303-3.
[9] ZHAO H, LI F, XU S, et al. Restoration neurite growth by removing the blockage of endosome trafficking in Alzheimer-like mice[J]. Neurotherapeutics, 2025. DOI: 10.1016/j.neurot.2025.e00777.
[10] LIU Z, MENG X, LU R, et al. PBX1 improves cognition and reduces amyloid-β pathology in APP/PS1 mice by transcriptionally activating the CRTC2-CREB pathway[J]. Aging Cell, 2025: e70311.
[11] LUO H, MARRON FERNANDEZ DE VELASCO E, KIM J, et al. Membrane-associated estrogen receptor α prevents the amyloid β-induced suppression of GIRK channel activity in hippocampal neurons from female mice[J]. Biol Sex Differ, 2025, 16(1): 90.
[12] LIU L R, LI L, LU L L, et al. Ceftriaxone alleviates mitochondrial damage through the inhibition of extrasynaptic NMDA receptor-mediated changes in intracellular calcium levels to improve cognitive deficits in APP/PS1 mice[J]. Alzheimers Res Ther, 2025, 17(1): 253.
[13] GUO Z, NI H, LU Y, et al. TNEA regulates hippocampal oscillation by improving inhibitory synaptic plasticity to ameliorates cognitive impairment in Alzheimer’s disease[J]. Adv Sci: Weinh, 2025, 11:e10885.
[14] WANG J L, SHA X Y, SHAO Y, et al. Elucidating pathway-selective biased CCKBR agonism for Alzheimer’s disease treatment[J]. Cell, 2025. DOI: 10.1016/j.cell.2025.10.034.
[15] MAIOLI S, NALVARTE I, ANKARCRONA M, et al. Bioenergetics and lipid metabolism in Alzheimer’s disease: from cell biology to systemic health[J]. J Intern Med, 2025, 299(1):20-43.
[16] CHEN C, MO M, ÅKERMAN M, et al. Dynamic associations of cholinesterase inhibitors and memantine with cognitive trajectories in individuals with Alzheimer’s or mixed dementia: a real-world analysis using the quality registry SveDem[J]. Alzheimers Res Ther, 2025, 17(1): 256.
[17] LI L L, WANG R Z, WANG Z, et al. Safety and short-term outcomes of lecanemab for Alzheimer’s disease in China: a multicentre study[J]. Brain, 2025, 11:awaf427
[18] NASRALLAH I M, POLACEK C, FRECH F H, et al. Early Alzheimer’s disease patient care pathway and health system readiness: a framework for integrated care[J]. Alzheimers Dement: N Y, 2025, 11(4):e70162.
[19] KNOPMAN D S, JONES D T, GREICIUS M D. Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019[J]. Alzheimers Dement, 2021, 17(4): 696-701.
[20] ALQAHTANI S M, AL-KURAISHY H M, AL-GAREEB A I, et al. Pharmacological modulation of the PI3K/AKT/GSK3β axis: a new frontier in Alzheimer’s disease treatment[J]. Inflammopharmacology, 2025. DOI: 10.1007/s10787-025-02000-9.
[21] LEE H J, KANG S, JIN LEE Y, et al. Genetic knockdown of DYRK1A attenuates cognitive impairment, Aβ pathology, tauopathy and neuroinflammatory responses in mouse models of AD[J]. Front Immunol, 2025, 16: 1661791.
[22] WANG X, SUN G, FENG T, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression[J]. Cell Res, 2019, 29(10):787-803.
[23] XIAO S, CHAN P, WANG T, et al. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia[J]. Alzheimers Res Ther, 2021, 13(1):62.
[24] LI H, BRZOSTEK O, SHERMAN J, et al. Cyclic nucleotide phosphodiesterase 1 and cognitive impairment: mechanistic insights and therapeutic implications[J]. Biomed Pharmacother, 2025, 193: 118796.
[25] SUN T, LI Z, XIAO B, et al. Recent development in PDE4D-targeted inhibitors for Alzheimer’s disease therapy[J]. Eur J Med Chem, 2025, 302(Pt 3):118383.
[26] XIONG C, TANG Y, CHEN J, et al. Transplantation of hiPSC-derived pericytes rescues Alzheimer’s disease phenotypes in APOE4/4 mice through IGF2-rich apoptotic vesicles[J]. Transl Neurodegener, 2025, 14(1): 57.
[27] WANG X, WANG D, LIU J, et al. Systemic delivery of liposome-loaded microRNA-195 ameliorates spatial memory impairment in a rat model of chronic cerebral hypoperfusion[J]. Int J Biol Macromol, 2026, 336:149290.
[28] KUEHN J F, ZHANG Q, HESTON M B, et al. Fecal short-chain fatty acids vary by sex and amyloid status[J]. Alzheimers Dement, 2025, 21(11):e70877.
[29] JIA L, XIAO L, SONG X, et al. Postbiotics alleviate cognitive impairment and neuroinflammation via gut-brain axis and TLR4/MyD88/NLRP3 pathway[J]. Food Res Int, 2025, 222(Pt 2): 117708.
[30] BAEK H I, KWON S Y, NOH H J, et al. Efficacy and safety of Lactobacillus delbrueckii subsp. lactis CKDB001 supplementation on cognitive function in mild cognitive impairment: a randomized, double-blind, placebo-controlled clinical trial[J]. Nutrients, 2025, 17(20):3313.
[31] TONG P, LI X, LI S, et al. Integrated metabolomics, transcriptomics and network pharmacology analysis to reveal the mechanisms of Danggui Buxue Tang in treating Alzheimer’s disease[J]. Phytomedicine, 2025, 150: 157591.
[32] 蔡美云, 庄文欣, 吕娥, 等. 山奈酚通过抑制p38 MAPK通路减轻6-羟多巴胺(6-OHDA)诱导的PC12细胞炎症[J]. 细胞与分子免疫学杂志, 2020, 36(7): 583-589.
[33] 张云, 高博, 许海军. 柴胡皂苷D基于PI3K/AKT/FoxO1调节神经炎症发挥抗抑郁作用[J]. 实用药物与临床, 2021, 24(5): 395-399.

Research progress on drug targets for Alzheimer’s disease-related cognitive impairment

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Recommended 10

[1]	CHENG Yi, ZOU Ting, LI Lihua, ZHANG Lei, ZHOU Xiaohui. Study on the mechanism of lncRNA AL133415.1 in regulating vimentin gene expression in SH-SY5Y cells [J]. Practical Geriatrics, 2026, 40(2): 126-131.
[2]	ZHONG Hailong, ZHONG Changzheng, ZHONG Qiong, WANG Kuiyuan, GUO Yanyan, HU Jianhua. Impact of artificial intelligence-assisted multi-cognitive domain training on elderly patients with mild cognitive impairment: a randomized controlled trial among community-dwelling elderly individuals [J]. Practical Geriatrics, 2026, 40(2): 159-163.
[3]	LUO Jing, ZHANG Yufeng, GAO Xiaolong, GU Guojun. Application of amide proton transfer magnetic resonance imaging in early diagnosis of Alzheimer’s disease [J]. Practical Geriatrics, 2026, 40(2): 164-168.
[4]	YANG Xin, SHI Shengliang. Research progress on the pathways of enhancing and restoring lysosomal function in Alzheimer’s disease [J]. Practical Geriatrics, 2026, 40(2): 180-184.
[5]	HU Yue, TANG Xiaojia, XU Jun. Research progress of Parkinson’s disease-related rapid eye movement sleep behavior disorder [J]. Practical Geriatrics, 2026, 40(2): 201-205.
[6]	WANG Jinfeng, SONG Jiao, JIANG Yangyang, YANG Xue, LI Ying. Association between sleep quality and depressive symptoms in residents with cognitive impairment residing in nursing homes [J]. Practical Geriatrics, 2026, 40(1): 16-20.
[7]	WANG Yifang, LI Tingting, WU Jin. Research progress on pathogenesis, diagnosis and treatment of vascular cognitive impairment [J]. Practical Geriatrics, 2026, 40(1): 78-82.
[8]	HE Haihua, LIU Gaoshuang, OUYANG Xiaojun. Effects and mechanisms of probiotics on sarcopenia complicated with cognitive impairment [J]. Practical Geriatrics, 2026, 40(1): 83-88.
[9]	ZHENG Aiyu, SUN Xin, YIN Yi, LI Xianwen. Application of dual-task training in elderly patients with chronic obstructive pulmonary disease and cognitive impairment [J]. Practical Geriatrics, 2026, 40(1): 89-93.
[10]	WANG Miaohui, FAN Xuhang, CHEN Siyao, YANG Xiaojuan. Research progress on the correlation between Alzheimer’s disease and osteoporosis [J]. Practical Geriatrics, 2025, 39(9): 937-941.
[11]	YANG Huijuan, LIU Shunying, SU Jing, ZENG Liting. Advances in the application of artificial intelligence in the full-course management of Alzheimer’s disease [J]. Practical Geriatrics, 2025, 39(8): 768-772.
[12]	ZHONG Yi, FENG Yue, ZHANG Xinlong, DING Rui, SI Yanna. Research progress in single-cell RNA sequencing for Alzheimer’s disease [J]. Practical Geriatrics, 2025, 39(8): 857-861.
[13]	CHANG Lin, GAO Yonghong. Research progress of inflammation and cognitive impairment [J]. Practical Geriatrics, 2025, 39(6): 547-550.
[14]	GU Xingyue, GAO Wei, LU Xiang. Advances in the study of enzymatic protein glycosylation in Alzheimer’s disease [J]. Practical Geriatrics, 2025, 39(6): 631-635.
[15]	WANG Yun, FU Liping. Significance of retinal structural and functional changes in the diagnosis of Alzheimer’s disease in high-altitude regions [J]. Practical Geriatrics, 2025, 39(5): 461-465.